This technology involves an oral available developmental drug candidate, DBPR728, that demonstrated in vivo efficacy in promoting the degradation of the MYC oncoprotein and inhibiting glycolysis of cancer cells, thereby inducing cancer cell apoptosis. Clinically, this technology primarily targets diseases such as small cell lung cancer and triple-negative breast cancer, which acquired MYC gene amplification.

The MYC oncoprotein is a transcription factor responsible for carcinogenesis and has been considered an undruggable drug target for the past forty years. The oral available DBPR728 developmental drug candidate breaks through this previous notion by using a small molecule to promote the degradation of the MYC oncoprotein. DBPR728 is able to induce regression and even complete remission of various solid tumors in mouse models, indicating promising potential for clinical development.

The oral available DBPR728 has clinical potential to treat cancers with MYC gene amplification, such as lung cancer, liver cancer, breast cancer, lymphoma, prostate cancer, and endometrial cancer. We have currently selected small cell lung cancer and triple-negative breast cancer as the primary disease indications.